BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...ADC in EGFR-mutated NSCLCDaiichi Sankyo Co. Ltd. (Tokyo:4568) presented Phase I data for patritumab deruxtecan (U3-1402...
BioCentury | Sep 13, 2019
Clinical News

Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

...Ltd. (Tokyo:4568) presented at the World Conference on Lung Cancer meeting in Barcelona data showing U3-1402...
...Programmed cell death 1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 BioCentury Staff U3-1402 Ocrevus...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

...tumors, AML Ph I PLX2853 Bromodomain containing 4 (BRD4) inhibitor AML, solid tumors Ph I U3-1402...
...inhibitor. Among three ADCs that could contribute to its 2025 tally, one has first-in-class potential. U3-1402...
...results presented in October showed that in 42 evaluable HER3-positive breast cancer patients treated with U3-1402...
BioCentury | Jul 13, 2018
Clinical News

Daiichi reports Phase I responses for U3-1402 in HER3-positive breast cancer

...Daiichi Sankyo Co. Ltd. (Tokyo:4568) said U3-1402 led to a confirmed overall response rate (ORR) of...
...is available. The preliminary data were from patients who received 1.6-8 mg/kg doses of IV U3-1402...
...breast cancer who have received six or fewer prior chemotherapy regimens to determine a recommended U3-1402...
BioCentury | Jan 20, 2017
Clinical News

U3-1402: Ph I/II started

...U3-1402 every 3 weeks in about 80 patients. A dose-escalation part will evaluate 1.6-9.7 mg/kg U3-1402...
...standard treatment or for whom no standard treatment is available. A dose-finding part will test U3-1402...
...who have received ≤6 prior chemotherapy regimens. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: U3-1402...
Items per page:
1 - 5 of 5